



## NCCP NATIONAL EXECUTIVE TEAM MEETING

Date: Monday 11<sup>th</sup> September 2023 @ 10.30am, MS teams

Present: R. Ó Laoide (Chair), F. Bonas, C. Faul, T. Hanan, P. Heckmann, M. Keane and T. McCarthy

Apologies: P. Cafferty and A. Hill

Invited: R. Parkin (Item A1), D. O'Shea and E. Conneally (Item A1), E. O'Toole (Item E1), L. Mullen and

D. Thomas (Item E3), R. Ryan, S. Fox

		I
A. PRI	ESENTATIONS	
A1	Update on Haemato-oncology was provided by Dr. E.Conneally and Dr. D. O'Shea	
A2	Update on Gynae Oncology was provided by Dr. M. O'Leary	
B. MI	NUTES & MATTERS ARISING	
B1	Minutes of the previous meeting	
	The minutes of the EMT meetings held on 10 <sup>th</sup> July 2023 were agreed.	
B2	Matters Arising	
C DIRE	CTOR's ITEMS	
C1	<ul> <li>National Service Plan</li> <li>Bids have been submitted through DOH Estimates process and HSE Service Planning process</li> </ul>	
	<ul> <li>Health Regions</li> <li>Details to be clarified on the operation of the regions</li> <li>New Regional Executive Officers expected to be in place early 2024.</li> </ul>	
	<ul> <li>Stakeholder events</li> <li>EU Cancer Mission day – September 26<sup>th</sup> Minister for Health and members of the EU Cancer Mission Board will attend.</li> <li>AICRI Showcase – September 27<sup>th</sup> – showcasing various research initiatives by AICRI partners.</li> <li>Official opening of Saolta Radiation Oncology Centre, Galway–October 20<sup>th</sup> by Minister for Health</li> </ul>	
D. STAN	NDING ITEMS	
D1	<ul> <li>An Introductory DigiCan Train workshop for all EU participants was held in March</li> <li>Cancer Mission Hubs –NCCP are leading on this project, with AICRI as the other Irish collaborating body. The project is underway and has a three-year timeframe.</li> </ul>	
	Action:	R.Ryan
	<ul> <li>Documents to be circulated on EU Cancer Mission Hubs</li> </ul>	·····yaii

E1	Evidence and Quality Hub (F. Bonas)	
	An overview of the MRI Prostate Calculator was provided by E. O'Toole.	
	Action:	
	Action	
	<ul> <li>To be discussed with Prostate Clinical Leads Group</li> </ul>	E. O'Toole
	An update was provided on Evidence and Quality programme workstreams by E. O'Toole.	
E2	Cancer Intelligence (P. Cafferty)	
	KPI performance was discussed	
	Reduction in some KPIs due to delays in accessing diagnostics and staffing	
	Actions:	
	<ul> <li>Minor format amendments to be made to Radiotherapy KPI 3 document</li> <li>Further stakeholder engagement to be sought and national executive to</li> </ul>	CI team
	discuss again in October.	J. Caill
E3	Public Health, Community Oncology and Prevention/Early Detection (T. McCarthy)	
	Update provided by D. Thomas and L. Mullen on the Alliance draft Annual	
	Report.	
	There are currently 5 of 6 posts filled in Community Health Promotion	
E4	Cancer Nursing (T Hanan)	
	Meeting with CPAC to discuss the Acute Oncology Nursing service to take	
	place on September 19th.	
ГГ	Surgical Disagraphy (A. Hill)	
E5	Surgical Programme (A. Hill)  No update at this meeting	
	no apadic at this meeting	
<b>E6</b>	Radiation Oncology (C. Faul/F. Bonas)	
	Recruitment of Radiation Therapists remains challenging and is	
	significantly impacting KPIs	
	Overtime initiative for Radiation Therapists has been extended for the	
	next 3 months.	
	<ul> <li>A report on the National Review of Radiation Therapists by HSE HR and SIPTU is pending.</li> </ul>	
	Actions:	
	<ul> <li>Report on the National Review of Radiation Therapists to be shared with</li> </ul>	F. Bonas/C. Faul
	R. Ó Laoide once published	
	<ul> <li>Update on equipment replacement programme to be provided by</li> </ul>	F. Bonas/
	Business & Planning team in October	P. Cafferty
E7	Systemic Therapy Programme [Medical Oncology/Haemato-oncology]	
	(M Keane)	
	Newly Approved Medical Oncology and Haemato-oncology Medicines,	
	Nivolumab, Olaparib and Zanubrutinib. 01/09/2023	
	Medical Oncology KPIs	

DATE OF NEXT MEETING  Monday 09 <sup>th</sup> October 2023 @ 10.30am			
	n/a		
G	АОВ		
	n/a		
F	FOR INFORMATION		
	No update at this meeting.		
E9	Cancer Networks (F Bonas)		
E8	<ul> <li>National Cancer Information System (NCIS) – M. Keane/P. Heckmann</li> <li>Roll out is continuing –</li> <li>14 hospitals now live – covering ~ 60% of SACT activity and ~ 40% of tumour conferences when fully utilised.</li> <li>Activity on the system continues to increase significantly.</li> <li>SVUH and UHL tentatively scheduled for Q4 2023</li> <li>Beaumont Hospital and Galway University Hospital continue to expand the use of the Tumour Board functionality with Neuro-Oncology and Prostate MDMs being some of the latest additions.</li> <li>There are now 532 Regimens approved for use in the system, to date in excess of 300 regimens have been used to create therapy plans for patients.</li> </ul>		
	Work is on-going – interim report expected Q4 2023		
	DoH – Mazars Implementation Group		
	<ul> <li>expected late Q4 2023.</li> <li>Roche Field Safety Notice (FSN) re SP142 is on-going</li> </ul>		
	Genetics/Genomics (P Heckmann)     Pathway for HRD testing in ovarian cancer agreed and in-country testing		
	<ul> <li>standardised approach</li> <li>KPIs are being shared with Acute Operations on an on-going basis</li> </ul>		
	<ul> <li>Discussion on-going with regard to including of the medical oncology KPI in the PR – 2025 and also review of the KPI definition to ensure a</li> </ul>		
	<ul> <li>Challenges on going in CUH, SVUH and SJH data is missing. Work is on- going on mitigation plans in place and expect improvements in the coming months</li> </ul>		